Home › Funds › Delaware/Macquarie › Nomura Healthcare Fund
Fund family: Delaware/Macquarie · Filed by DELAWARE GROUP EQUITY FUNDS IV (CIK 778108) · SEC series S000018873
Share classes and tickers: DLHAX (C000052257), DLHCX (C000052258), DLHIX (C000052260), DLRHX (C000052259)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 943 with, 20 against, 0 abstentions (not counted as with management). Shareholder proposals: 8 FOR, 11 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Delaware/Macquarie’s manager page (15,554 ballot items across 17 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Delaware/Macquarie | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 80.8% | 881 | 92.2% | 13,591 |
| Backed environmental and social shareholder proposals at US companies | n/a | 7 | 24.8% | 266 |
Each ballot item this fund voted is set against the votes of the other Delaware/Macquarie funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Delaware/Macquarie funds on 2 items (2.8% of the 72 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Delaware/Macquarie funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Pfizer Inc. | 2026-04-23 | Election of Directors: Scott Gottlieb | Against | FOR — 4 of 4 Delaware/Macquarie funds | Against | Elected, 96.3% support |
| Merck & Co., Inc. | 2026-05-26 | Election of Directors: Patricia F. Russo | Against | FOR — 2 of 3 Delaware/Macquarie funds | Against | Elected, 88.3% support |
Download all 2 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 69.0% of this fund’s 963 such votes could be given a sector; the other 299 (31.0%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 647 | 18 | 2.8% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 523 | 0 |
| Compensation | 99 | 1 |
| Audit-related | 90 | 0 |
| Say-on-Pay | 86 | 0 |
| Capital Structure | 81 | 0 |
| Corporate Governance | 70 | 12 |
| Extraordinary Transactions | 8 | 0 |
| Other Social Issues | 5 | 4 |
| Shareholder Rights and Defenses | 4 | 0 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | June 12, 2026 | $45M | 7 | 0 |
| Eli Lilly and Company | May 4, 2026 | $37M | 10 | 2 |
| AbbVie Inc. | May 8, 2026 | $37M | 8 | 1 |
| Gilead Sciences, Inc. | April 30, 2026 | $35M | 15 | 3 |
| Pfizer Inc. | April 23, 2026 | $33M | 16 | 1 |
| Merck & Co., Inc. | May 26, 2026 | $31M | 18 | 3 |
| UnitedHealth Group Incorporated | June 1, 2026 | $29M | 12 | 1 |
| Elevance Health, Inc. | May 13, 2026 | $28M | 6 | 1 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 13, 2026 | Elevance Health, Inc. | Shareholder Proposal Requesting an Independent Study on the Impact of Prohibiting Corporate Contributions to Partisan 527 Tax-Exempt Political Groups. Shareholder proposal | For | Against |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | For | Against |
Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.
969 ballot items at 105 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Nomura Healthcare Fund (DLHAX) voted at 105 shareholder meetings of 97 companies, on 969 ballot items in all. Where management made a recommendation, the fund followed it on 97.9% of the items and voted against it 20 times. Its most frequent area of disagreement was corporate governance (12 of its votes against management). It voted on 19 shareholder proposals. It voted FOR the board's own proposals less often than Delaware/Macquarie's funds as a whole (80.8% against 92.2%). It voted differently from most Delaware/Macquarie funds on 2 items. 1 of its meetings was contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Delaware/Macquarie’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.